Rhodes, Kirsty
Jenkins, Martin
de Nigris, Enrico
Aurivillius, Magnus
Ouwens, Mario
Funding for this research was provided by:
AstraZeneca
Article History
Received: 21 April 2021
Accepted: 19 April 2022
First Online: 25 May 2022
Declarations
:
: All methods were carried out in accordance with relevant guidelines and regulations. The protocol and informed consent form for the ETHOS study were approved by the appropriate Institutional Review Board, independent ethics committee or health authority, including Johns Hopkins Medicine Office of Human Subject Institutional Review Board, 1620 McElderry Street, Reed Hall, Suite B-130, Baltimore, MD 21205–1911 (see the ‘Independent Ethics Committees/Institutional Review Boards consulted’ section of the Supplementary Information for a full list). Written informed consent was obtained prospectively from all patients before screening. An independent data monitoring committee and an independent clinical end-point committee reviewed safety data throughout the ETHOS study, including cardiovascular and cerebrovascular events, pneumonia, and cause-specific deaths.
: Not applicable.
: KR, MJ, MA and MO are all employees and shareholders of AstraZeneca. EdN was an employee of AstraZeneca at the time of the analysis.